The Fleecing of Cancer Patients
I have said it before that drug companies are more likely to bring out a product that relieves symptoms than provide a cure.
It's like you don't want to build the perfect car or people only need to buy one and not replace it, it's better that they wear out and they have to keep repairing them and eventually buy a new one. This ensures you get money over a period of time and not just once at the beginning.
It's the same with medications it seems, why cure someone when they can keep paying and paying, and who better than those poor desperate souls that will die soon if they don't get your medicine?
"The fleecing of cancer patients
I don’t often criticize the pharmaceutical industry, because I am a capitalist at heart, and there are enough other, often ill-informed people out there to do it for me. I don’t begrudge the pharmaceutical industry its high prices on patent medicines. I do think that some of their practices are a little over the top. On the other hand, some of the major players in Big Pharma are considered some of the world’s most ethical companies.
Imagine my dismay, then, when I came across an article that I’d printed out from the New York Times back on February 15 about Avastin, a drug from Genentech that shows significant effect in terminal cancer patients suffering from colon cancer as well as late-stage breast and lung cancer. Avastin will cost upwards of $100,000 a year for treatment. While most patients that take Avastin won’t last a year, that breaks down to over $8,000 a month. (The average colon cancer patient on Avastin takes it for 11 months.) Naturally, insurance companies are reluctant to pay for the medication, and one can hardly blame them. (Contrary to popular belief, most insurance companies are not minting money.)
$8,000 a month.
What makes this price exorbitant even by my standards is how the price is justified. While there are drugs out there that are more expensive than Avastin, most of those drugs are for niche diseases which afflict only a handful of people. Avastin, on the other hand can be used for thousands of patients. Traditionally the high price of patent medicines has been explained away by talk of R&D costs, which as I mentioned yesterday, average $500 million per New Chemical Entity (NCE) regardless of whether that NCE actually makes it to market or not. Genentech, however, has justified their high price by citing the inherent value of life-sustaining therapies. That is, they’re using a patient’s desire to stay alive to justify the high cost of their drugs.
This, in my opinion, has crossed the line from being ethical to simple profiteering. Some patients aren’t taking other, similar medications because they can’t afford to, or because the benefits don’t outweigh the costs: Avastin and Tarceva (another cancer drug) cure cancer. They simply prolong life."
http://polyscience.org/2006/03/overpriced-avastin/